Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 361 Lung Neoplasms 195 Breast Neoplasms 163 Ovarian Neoplasms 129 Triple Negative Breast Neoplasms 79 Squamous Cell Carcinoma of Head and Neck 73 Small Cell Lung Carcinoma 67 Fallopian Tube Neoplasms 56 Head and Neck Neoplasms 46 Carcinoma, Ovarian Epithelial 44 Neoplasms 40 Neoplasm Metastasis 39 Esophageal Neoplasms 36 Adenocarcinoma of Lung 36 Esophageal Squamous Cell Carcinoma 29 Prostatic Neoplasms 27 Endometrial Neoplasms 27 Uterine Cervical Neoplasms 23 Brain Neoplasms 23 Central Nervous System Neoplasms 22 Urinary Bladder Neoplasms 21 Carcinoma, Squamous Cell 21 Recurrence 20 Neuroblastoma 20 Lymphoma, Large B-Cell, Diffuse 20 Melanoma 19 Lymphoma 19 Carcinoma 19 Adenocarcinoma, Bronchiolo-Alveolar 18 Testicular Neoplasms 15

Interventions

Paclitaxel 2 liposomal doxorubicin 1 Tocotrienols 1 Platinum Compounds 1 EP-100 membrane-disrupting peptide 1 Carboplatin 1 Bevacizumab 1 AC 7700 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Cancer Recurrent × Carboplatin × Clear all

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡